P

Prolaio

Decentralized cardiovascular trials with wearables

Data Science – Intern - Biomarkers

Summer 2026Updated
$50/hr
Internship
Master's, PhD
Chicago, IL, USA
In Person
Data & AnalyticsData Science

About the job

Requirements
  • Currently enrolled in a Master’s or PhD program in Data Science, Electrical Engineering, Biomedical Engineering, Computer Science, or a related quantitative field.
  • Strong proficiency in Python and deep learning frameworks (e.g., PyTorch or TensorFlow) with a specific focus on time series or signal data.
  • Familiarity with digital signal processing techniques, such as Fourier transforms, wavelet analysis, and windowing methods for physiological data.
  • Solid understanding of modern machine learning architectures (Convolutional Neural Networks, Recurrent Neural Networks, Transformers) and experience with Transfer Learning or fine-tuning large-scale models.
  • Experience working with real-world sensor data, handling irregular sampling rates, and managing large-scale longitudinal datasets.
Responsibilities
  • Test existing and fine-tune deep learning architectures for time series data, specifically utilizing transfer learning techniques to adapt pre-trained ECG-based cardiac models for new physiological signal tasks.
  • Build and optimize Python-based signal processing workflows to handle noisy, real-world sensor data, including filtering, feature extraction, and artifact removal.
  • Research and implement emerging foundational time series models to evaluate their zero-shot or few-shot performance on proprietary longitudinal cardiac datasets.
  • Design rigorous validation frameworks comparing model outputs against a clinician-verified ground truth to establish metrics like Mean Absolute Error and Intraclass Correlation.
  • Maintain a clean, documented, and reproducible code repository that transforms raw high-frequency signals into structured, analysis-ready biomarker datasets.
Desired Qualifications
  • None

About the company

Prolaio builds cardiovascular clinical research infrastructure that turns homes into trial sites using medical-grade wearables to capture continuous real-world heart data. Its intelligence engine translates signals into clinically robust endpoints and FDA-cleared digital biomarkers. Sponsors use the platform for recruitment, 24/7 data capture, adaptive analytics, and dashboards, enabling fully managed real-world trials and post-discharge monitoring. The goal is to make cardiovascular trials faster, scalable, and more accurate by leveraging home data and standardized digital endpoints.

Company Size

51-200

Company Stage

Early VC

Total Funding

$25.5M

Headquarters

Chicago, IL

Founded

2022

Get referred to Prolaio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kardigan's August 11, 2026 results credit Prolaio for three late-stage programs, proving internal dependence.
  • Prolaio's FDA-cleared eVO2peak and AFib burden strengthen cardiovascular endpoint differentiation immediately.
  • New Prolaio strategy and customer-success roles in 2026 signal active commercialization, not shutdown.

What critics are saying

  • Kardigan controls Prolaio now, so standalone SaaS independence ended by September 2026.
  • Prolaio still shows customer-success hiring in 2026, signaling heavy services burden and margin pressure.
  • Competitors like Medable, ActiGraph, and Biofourmis sell broader decentralized-trial stacks and unbundle Prolaio's niche.

What makes Prolaio unique

  • Kardigan bought Prolaio on March 27, 2025, bundling data with therapeutics.
  • Prolaio runs FDA-cleared cardiovascular biomarkers from 4 million on-body hours across 26 countries.
  • Its platform converts home wearables into trial endpoints, dashboards, and structured regulatory data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

2%

1 year growth

-3%

2 year growth

3%
Business Wire
Mar 28th, 2025
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform

Kardigan, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired Prolaio, a clinical intelligence comp...

U.S. Securities and Exchange Commission
Sep 13th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

INACTIVE